文献速递系统性红斑狼疮其他结缔组织病

利妥昔单抗治疗儿童期起病系统性红斑狼疮的适应证、疗效与安全性:JIR队列回顾性研究

Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该全国性回顾性研究基于JIR队列数据库,分析2009年7月至2023年6月接受利妥昔单抗治疗的41例儿童期起病系统性红斑狼疮患者,主要适应证为狼疮肾炎(51.2%)、持续性多关节炎(19.5%)和难治性血细胞减少(12.2%);治疗后3个月和6个月SLEDAI-2K评分显著改善(P < 0.001),糖皮质激素用量从0.93 mg/kg降至0.39 mg/kg(P = 0.001),17%患者出现不良事件,其中7.3%发生过敏反应。

要点

  • 利妥昔单抗主要用于难治性儿童期起病系统性红斑狼疮的狼疮肾炎、持续性多关节炎和难治性血细胞减少。
  • 治疗后3个月和6个月疾病活动度显著改善(SLEDAI-2K,P < 0.001),激素用量显著降低(P = 0.001)。
  • 17%患者出现不良事件,7.3%发生过敏反应;末次输注后1年52.5%患儿无需升级基线免疫抑制治疗或启用新治疗方案。

核心结论

  • 利妥昔单抗治疗难治性儿童期起病系统性红斑狼疮可降低疾病活动度和激素依赖,安全性可接受。
  • 原文结论指出需要进一步研究和国际合作来验证这些发现。

研究设计与样本

  • 全国性回顾性研究,分析JIR队列数据库中2009年7月至2023年6月接受利妥昔单抗治疗的儿童期起病系统性红斑狼疮患者数据。
  • 共纳入41例患者,85.4%为女孩,平均诊断年龄11.7岁。

主要发现

  • 利妥昔单抗平均在诊断后16个月给药;治疗开始时87%患者曾接受或正在接受糖皮质激素,21%使用NSAIDs,82%使用免疫抑制剂。
  • 主要适应证为狼疮肾炎(51.2%)、持续性多关节炎(19.5%)和难治性血细胞减少(12.2%)。
  • 输注后3个月和6个月SLEDAI-2K评分显著改善(P < 0.001),糖皮质激素用量从0.93 mg/kg降至0.39 mg/kg(P = 0.001),相关生物标志物改善。
  • 17%患者发生不良事件,其中7.3%发生过敏反应。
  • 末次输注后1年,52.5%的患儿无需增加基线免疫抑制治疗或启用新治疗方案。

关键数值与推荐

  • 原文未报告具体推荐条款或阈值标准。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出需要进一步研究和国际合作来验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Childhood-onset systemic lupus erythematosus (cSLE) is a rare autoimmune disease with significant morbidity. Although B cell-depleting agents show promise for refractory cSLE, there is limited research on rituximab therapy in children. This study aimed to retrospectively assess the indications, efficacy, and safety of RTX in cSLE, using data from the Juvenile Inflammatory Rheumatism (JIR) cohort database. METHODS: A national retrospective study analysed data from the JIR cohort for cSLE patients treated with RTX from July 2009 to June 2023. RESULTS: Forty-one patients received RTX over 14 years; 85.4% were girls and mean age at diagnosis was 11.7 years. RTX was administered on average 16 months post-diagnosis. At treatment initiation, 87% either had received or were receiving corticosteroids, 21% NSAIDs and 82% immunosuppressants. Main indications for RTX were lupus nephritis (51.2%), persistent polyarthritis (19.5%) and refractory cytopenias (12.2%). Significant improvements in disease activity were observed at 3 and 6 months post-RTX infusion, indicated by the SLEDAI-2K score (P < 0.001), along with a notable reduction in corticosteroid usage (from 0.93 mg/kg to 0.39 mg/kg; P = 0.001) and improvements in relevant biomarkers. Adverse effects occurred in 17% of patients, with 7.3% experiencing anaphylactic reactions. One year following the last infusion, 52.5% of the paediatric subjects did not necessitate an increase in their baseline immunosuppressive therapy or the initiation of a novel treatment modality. CONCLUSIONS: RTX in refractory cSLE reduced disease activity and steroid dependence with an acceptable safety profile. Further research and international collaboration are needed to validate these findings.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cognard J, Pietrement C, Laurent A, et al. Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort. Rheumatology (Oxford). 2025. PMID: 40279484. doi:10.1093/rheumatology/keaf231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。